Ketanserin in the treatment of peripheral vascular disease or hypertension in patients with diabetes mellitus: a review.
The available data on the use of ketanserin in diabetes mellitus have been reviewed. Ketanserin does not worsen glucose tolerance or destabilize diabetic control. Ketanserin can improve impairment of peripheral blood flow, and especially skin blood flow; the healing of cutaneous ulcers is improved; trophic skin changes are fewer; and there is a trend towards less limb amputations. Walking distance in diabetic claudicants is unaltered by ketanserin. Controlled trials in hypertensive diabetics have provided variable results, with a significant fall in arterial pressure in only one of five studies. As in nondiabetics, ketanserin generally lowers serum cholesterol. The electrocardiographic QTc interval is prolonged. Symptomatic side effects in diabetics are as those in nondiabetic subjects.
Janssens
M
M
Janssen Research Foundation, Beerse, Belgium.
Symoens
J
J
Robertson
M P
MP
D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000378:metabolism; D003920:Diabetes Mellitus / Q000188:drug therapy*; D003925:Diabetic Angiopathies / Q000188:drug therapy*; D016523:Foot Ulcer / Q000188:drug therapy; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007650:Ketanserin / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D008875:Middle Aged; D012883:Skin Ulcer / Q000188:drug therapy
D001786:Blood Glucose; D008055:Lipids; D007650:Ketanserin